Go Pro
NASDAQ:ZSQR

Coeptis Therapeutics Q1 2025 Earnings Report

Coeptis Therapeutics logo
$10.99 0.00 (0.00%)
As of 07/2/2026 04:00 PM Eastern

Coeptis Therapeutics EPS Results

Actual EPS
-$1.11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Coeptis Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Coeptis Therapeutics Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Coeptis Therapeutics Earnings Headlines

Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
See More Coeptis Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Coeptis Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Coeptis Therapeutics and other key companies, straight to your email.

About Coeptis Therapeutics

Coeptis Therapeutics (NASDAQ:ZSQR), a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

View Coeptis Therapeutics Profile